We are live on
!
Find out more
SNNA
Sienna Biopharmaceuticals, Inc.
SNNA
SNNA
Delisted
SNNA was delisted on the 16th of December, 2019.
54 hedge funds and large institutions have $151M invested in Sienna Biopharmaceuticals, Inc. in 2018 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 26 increasing their positions, 10 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
160% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 10
14% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 7
2% more funds holding
Funds holding: 53 → 54 (+1)
0% more capital invested
Capital invested by funds: $151M → $151M (+$194K)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Holders
54
Holders Change
+1
Holders Change %
+1.89%
% of All Funds
1.23%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
8
Increased
26
Reduced
10
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$2.43M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$1.77M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.2M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.07M |
| 5 |
BlackRock
New York
|
+$475K |
